California-based Erasca announced Thursday it is expanding its existing partnership with Pfizer to assess ERAS-007 in combination with Pfizer’s Ibrance (palbociclib).
Tag Archive for: Pfizer
With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations.
The authorization applies for people unable to get updated Omicron-tailored boosters, or those who would choose not to receive any other booster dose.
Backed by Pfizer, Merck KGaA and J&J, Nucleome Therapeutics secured £37.5 million (about $42.16 million) in an oversubscribed Series A financing round to mine the dark genome for precision medicines for autoimmune diseases.
Pfizer and its German partner BioNTech said their COVID-19 vaccine booster, adapted for the BA.4 and the BA.5 subvariants, generated a strong immune response and was well tolerated in testing on humans.
Data recently unveiled showed GSK’s respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.
The Moderna COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to six years of age. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for administration at least two months following completion of primary or booster vaccination in children down to five years of age.
Drugmaker Viatris Inc. is considering a potential sale of its consumer health assets in Europe in a deal that could be valued at over 3 billion euros ($2.9 billion), Bloomberg News reported on Tuesday, citing people familiar with the matter.
The pharmaceutical giant, still riding high on the sales of Comirnaty and Paxlovid, is looking to a future of innovative oncology drugs and vaccines based on mRNA technology.
Although Pfizer has dominated the headlines with Comirnaty, it’s not the only company that has created a COVID-19 vaccine using mRNA technology. The biotechnology company Moderna received FDA authorization for its own mRNA COVID-19 vaccine, Spikevax, in December 2021 for administration in individuals 18 years old and older.
